News und Analysen

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 20, 2020, following release of its fourth

Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible ), a Research & Development company committed to scientific innovation for preventing and combating metabolic

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse der operativen Tätigkeit für das vierte Quartal und das Gesamtjahr 2019 bekannt.

„QIAGENs Ergebnisse des vierten

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2019.

“QIAGEN’s performance for the fourth quarter and full-year 2019

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that clinical translational data supporting the mechanism

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that it has entered into a definitive agreement to acquire substantially all the assets and certain

Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 second quarter ended Dec. 31, 2019.

All results presented in this press release reflect continuing operations

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die CE-Kennzeichnung und die Einführung des therascreen® PIK3CA RGQ PCR-Kits in Europa zur Identifizierung von

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the CE-marking and launch of its therascreen^® PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients

Veeva Systems (NYSE:VEEV) will announce financial results for its fourth quarter and full fiscal year which ended January 31, 2020 after market close on March 3, 2020. Veeva will host a conference

MEDICREA^® (Euronext Growth Paris : FR0004178572 – ALMED, PEA-PME eligible and OTCQX : MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling

Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca^® (rucaparib) is now available and reimbursed in France. Rubraca^® (rucaparib) is an option for monotherapy maintenance treatment for

Regulatory News:

Sensorion (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and

Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will present at the BIO CEO and

Regulatory News:

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent

Agilent Technologies Inc. (NYSE: A) today announced that it is joining forces with the Indian Institute of Technology Delhi (IIT Delhi) to promote biopharmaceutical research.

Agilent and IIT

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019.

Fourth quarter 2019 results:

• 
  Revenue of $953 million, a 10% increase compared

Agilent Technologies, Inc. (NYSE: A) will release first-quarter fiscal year 2020 financial results after the stock market closes on Feb. 18. The company will also host a live webcast of its